Correction: Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
Crossref DOI link: https://doi.org/10.1158/2159-8290.CD-20-0703
Published Online: 2020-07-01
Published Print: 2020-07-01
Update policy: https://doi.org/10.1158/crossmark_policy